KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Cash (2016 - 2025)

Historic Change in Cash for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to -$34.2 million.

  • Vertex Pharmaceuticals' Change in Cash fell 10520.47% to -$34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$300.3 million, marking a year-over-year increase of 9488.28%. This contributed to the annual value of -$5.8 billion for FY2024, which is 405182.53% down from last year.
  • Vertex Pharmaceuticals' Change in Cash amounted to -$34.2 million in Q3 2025, which was down 10520.47% from $296.6 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' Change in Cash's 5-year high stood at $1.3 billion during Q4 2022, with a 5-year trough of -$4.6 billion in Q2 2024.
  • In the last 5 years, Vertex Pharmaceuticals' Change in Cash had a median value of $296.6 million in 2025 and averaged -$54.8 million.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Change in Cash soared by 55496.28% in 2022, and later crashed by 63373.75% in 2024.
  • Vertex Pharmaceuticals' Change in Cash (Quarter) stood at $519.9 million in 2021, then skyrocketed by 156.78% to $1.3 billion in 2022, then crashed by 155.75% to -$744.3 million in 2023, then rose by 9.19% to -$675.9 million in 2024, then soared by 94.94% to -$34.2 million in 2025.
  • Its last three reported values are -$34.2 million in Q3 2025, $296.6 million for Q2 2025, and $113.2 million during Q1 2025.